Cost Effectiveness Analysis of The Use Of Daclatasvir + Asunaprevir in The Treatment of Patients with Chronic Hepatitis C in Peru

To evaluate the cost-effectiveness of DUAL [Daclatasvir (DCV) + Asunaprevir (ASV)] and different treatment regimens [Telaprevir (TVR) or Simeprevir (SMV), both with peginterferon-alpha and ribavirin (A/R)] in patients with Hepatitis C (HCV) genotype 1b from the perspective of Social Security in Peru.

Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: C Sanabria, R Roman, D Montano, D Mercado, G Valenzuela, JE Caporale Source Type: research